The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine
In response to the SARS-CoV-2 Delta variant, which partially escaped the vaccine-induced immunity provided by two doses of vaccination with CoronaVac (Sinovac), the National Vaccine Committee recommended the heterologous CoronaVac-ChAdOx1 (Oxford–AstraZeneca), a prime–boost vaccine regimen. This pil...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/4/536 |
| _version_ | 1797409110779494400 |
|---|---|
| author | Surakameth Mahasirimongkol Athiwat Khunphon Oraya Kwangsukstid Sompong Sapsutthipas Mingkwan Wichaidit Archawin Rojanawiwat Nuanjun Wichuckchinda Wiroj Puangtubtim Warangluk Pimpapai Sakulrat Soonthorncharttrawat Asawin Wanitchang Anan Jongkaewwattana Kanjana Srisutthisamphan Daraka Phainupong Naphatcha Thawong Pundharika Piboonsiri Waritta Sawaengdee Thitiporn Somsaard Kanokphon Ritthitham Supaporn Chumpol Nadthanan Pinyosukhee Rattanawadee Wichajarn Panadda Dhepakson Sopon Iamsirithaworn Supaporn Phumiamorn |
| author_facet | Surakameth Mahasirimongkol Athiwat Khunphon Oraya Kwangsukstid Sompong Sapsutthipas Mingkwan Wichaidit Archawin Rojanawiwat Nuanjun Wichuckchinda Wiroj Puangtubtim Warangluk Pimpapai Sakulrat Soonthorncharttrawat Asawin Wanitchang Anan Jongkaewwattana Kanjana Srisutthisamphan Daraka Phainupong Naphatcha Thawong Pundharika Piboonsiri Waritta Sawaengdee Thitiporn Somsaard Kanokphon Ritthitham Supaporn Chumpol Nadthanan Pinyosukhee Rattanawadee Wichajarn Panadda Dhepakson Sopon Iamsirithaworn Supaporn Phumiamorn |
| author_sort | Surakameth Mahasirimongkol |
| collection | DOAJ |
| description | In response to the SARS-CoV-2 Delta variant, which partially escaped the vaccine-induced immunity provided by two doses of vaccination with CoronaVac (Sinovac), the National Vaccine Committee recommended the heterologous CoronaVac-ChAdOx1 (Oxford–AstraZeneca), a prime–boost vaccine regimen. This pilot study aimed to describe the immunogenicity and adverse events of the heterologous CoronaVac-ChAdOx1 regimen, in comparison with homologous CoronaVac, and homologous ChAdOx1. Between May and August 2021, we recruited a total of 354 participants from four vaccination groups: the CoronaVac-ChAdOx1 vaccinee (<i>n</i> = 155), the homologous CoronaVac vaccinee (<i>n</i> = 32), the homologous ChAdOx1 vaccinee (<i>n</i> = 47), and control group of COVID-19 patients (<i>n</i> = 120). Immunogenicity was evaluated by measuring the level of IgG antibodies against the receptor-binding domain (anti-SRBD) of the SARS-CoV-2 spike protein S1 subunit and the level of neutralizing antibodies (NAbs) against variants of concern (VOCs) using the plaque reduction neutralization test (PRNT) and pseudovirus neutralization test (pVNT). The safety profile was recorded by interviewing at the 1-month visit after vaccination. The anti-SRBD level after the second booster dose of the CoronaVac-ChAdOx1 group at 2 weeks was higher than 4 weeks. At 4 weeks after the second booster dose, the anti-SRBD level in the CoronaVac-ChAdOx1 group was significantly higher than either homologous CoronaVac, the homologous ChAdOx1 group, and Control group (<i>p</i> < 0.001). In the CoronaVac-ChAdOx1 group, the PRNT<sub>50</sub> level against the wild-type (434.5 BAU/mL) was the highest; followed by Alpha variant (80.4), Delta variant (67.4), and Beta variant (19.8). The PVNT<sub>50</sub> level was also found to be at its highest against the wild-type (432.1); followed by Delta variants (178.3), Alpha variants (163.9), and Beta variant (42.2), respectively. The AEs in the CoronaVac-ChAdOx1 group were well tolerated and generally unremarkable. The CoronaVac-ChAdOx1 heterologous regimen induced higher immunogenicity and a tolerable safety profile. In a situation when only CoronaVac-ChAdOx1 vaccines are available, they should be considered for use in responding to the Delta variant. |
| first_indexed | 2024-03-09T04:08:36Z |
| format | Article |
| id | doaj.art-518ddbc5fd4a4ebe97eaf658e10ba8ca |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T04:08:36Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-518ddbc5fd4a4ebe97eaf658e10ba8ca2023-12-03T14:02:46ZengMDPI AGVaccines2076-393X2022-03-0110453610.3390/vaccines10040536The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) VaccineSurakameth Mahasirimongkol0Athiwat Khunphon1Oraya Kwangsukstid2Sompong Sapsutthipas3Mingkwan Wichaidit4Archawin Rojanawiwat5Nuanjun Wichuckchinda6Wiroj Puangtubtim7Warangluk Pimpapai8Sakulrat Soonthorncharttrawat9Asawin Wanitchang10Anan Jongkaewwattana11Kanjana Srisutthisamphan12Daraka Phainupong13Naphatcha Thawong14Pundharika Piboonsiri15Waritta Sawaengdee16Thitiporn Somsaard17Kanokphon Ritthitham18Supaporn Chumpol19Nadthanan Pinyosukhee20Rattanawadee Wichajarn21Panadda Dhepakson22Sopon Iamsirithaworn23Supaporn Phumiamorn24Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandMedical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandInstitute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok 10400, ThailandInstitute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandInstitute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok 10400, ThailandNational Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandMedical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandMedical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandMedical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandMedical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandVirology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, ThailandVirology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, ThailandEpidemiology Division, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, ThailandInstitute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok 10400, ThailandMedical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandMedical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandMedical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandInstitute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandInstitute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandInstitute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandMedical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandMedical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandMedical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandEpidemiology Division, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, ThailandInstitute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, ThailandIn response to the SARS-CoV-2 Delta variant, which partially escaped the vaccine-induced immunity provided by two doses of vaccination with CoronaVac (Sinovac), the National Vaccine Committee recommended the heterologous CoronaVac-ChAdOx1 (Oxford–AstraZeneca), a prime–boost vaccine regimen. This pilot study aimed to describe the immunogenicity and adverse events of the heterologous CoronaVac-ChAdOx1 regimen, in comparison with homologous CoronaVac, and homologous ChAdOx1. Between May and August 2021, we recruited a total of 354 participants from four vaccination groups: the CoronaVac-ChAdOx1 vaccinee (<i>n</i> = 155), the homologous CoronaVac vaccinee (<i>n</i> = 32), the homologous ChAdOx1 vaccinee (<i>n</i> = 47), and control group of COVID-19 patients (<i>n</i> = 120). Immunogenicity was evaluated by measuring the level of IgG antibodies against the receptor-binding domain (anti-SRBD) of the SARS-CoV-2 spike protein S1 subunit and the level of neutralizing antibodies (NAbs) against variants of concern (VOCs) using the plaque reduction neutralization test (PRNT) and pseudovirus neutralization test (pVNT). The safety profile was recorded by interviewing at the 1-month visit after vaccination. The anti-SRBD level after the second booster dose of the CoronaVac-ChAdOx1 group at 2 weeks was higher than 4 weeks. At 4 weeks after the second booster dose, the anti-SRBD level in the CoronaVac-ChAdOx1 group was significantly higher than either homologous CoronaVac, the homologous ChAdOx1 group, and Control group (<i>p</i> < 0.001). In the CoronaVac-ChAdOx1 group, the PRNT<sub>50</sub> level against the wild-type (434.5 BAU/mL) was the highest; followed by Alpha variant (80.4), Delta variant (67.4), and Beta variant (19.8). The PVNT<sub>50</sub> level was also found to be at its highest against the wild-type (432.1); followed by Delta variants (178.3), Alpha variants (163.9), and Beta variant (42.2), respectively. The AEs in the CoronaVac-ChAdOx1 group were well tolerated and generally unremarkable. The CoronaVac-ChAdOx1 heterologous regimen induced higher immunogenicity and a tolerable safety profile. In a situation when only CoronaVac-ChAdOx1 vaccines are available, they should be considered for use in responding to the Delta variant.https://www.mdpi.com/2076-393X/10/4/536homologousheterologousCOVID-19 vaccineheterologous prime-boostimmunogenicityinactivated |
| spellingShingle | Surakameth Mahasirimongkol Athiwat Khunphon Oraya Kwangsukstid Sompong Sapsutthipas Mingkwan Wichaidit Archawin Rojanawiwat Nuanjun Wichuckchinda Wiroj Puangtubtim Warangluk Pimpapai Sakulrat Soonthorncharttrawat Asawin Wanitchang Anan Jongkaewwattana Kanjana Srisutthisamphan Daraka Phainupong Naphatcha Thawong Pundharika Piboonsiri Waritta Sawaengdee Thitiporn Somsaard Kanokphon Ritthitham Supaporn Chumpol Nadthanan Pinyosukhee Rattanawadee Wichajarn Panadda Dhepakson Sopon Iamsirithaworn Supaporn Phumiamorn The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine Vaccines homologous heterologous COVID-19 vaccine heterologous prime-boost immunogenicity inactivated |
| title | The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine |
| title_full | The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine |
| title_fullStr | The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine |
| title_full_unstemmed | The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine |
| title_short | The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine |
| title_sort | pilot study of immunogenicity and adverse events of a covid 19 vaccine regimen priming with inactivated whole sars cov 2 vaccine coronavac and boosting with the adenoviral vector chadox1 ncov 19 vaccine |
| topic | homologous heterologous COVID-19 vaccine heterologous prime-boost immunogenicity inactivated |
| url | https://www.mdpi.com/2076-393X/10/4/536 |
| work_keys_str_mv | AT surakamethmahasirimongkol thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT athiwatkhunphon thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT orayakwangsukstid thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT sompongsapsutthipas thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT mingkwanwichaidit thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT archawinrojanawiwat thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT nuanjunwichuckchinda thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT wirojpuangtubtim thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT waranglukpimpapai thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT sakulratsoonthorncharttrawat thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT asawinwanitchang thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT ananjongkaewwattana thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT kanjanasrisutthisamphan thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT darakaphainupong thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT naphatchathawong thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT pundharikapiboonsiri thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT warittasawaengdee thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT thitipornsomsaard thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT kanokphonritthitham thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT supapornchumpol thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT nadthananpinyosukhee thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT rattanawadeewichajarn thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT panaddadhepakson thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT soponiamsirithaworn thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT supapornphumiamorn thepilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT surakamethmahasirimongkol pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT athiwatkhunphon pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT orayakwangsukstid pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT sompongsapsutthipas pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT mingkwanwichaidit pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT archawinrojanawiwat pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT nuanjunwichuckchinda pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT wirojpuangtubtim pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT waranglukpimpapai pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT sakulratsoonthorncharttrawat pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT asawinwanitchang pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT ananjongkaewwattana pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT kanjanasrisutthisamphan pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT darakaphainupong pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT naphatchathawong pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT pundharikapiboonsiri pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT warittasawaengdee pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT thitipornsomsaard pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT kanokphonritthitham pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT supapornchumpol pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT nadthananpinyosukhee pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT rattanawadeewichajarn pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT panaddadhepakson pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT soponiamsirithaworn pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine AT supapornphumiamorn pilotstudyofimmunogenicityandadverseeventsofacovid19vaccineregimenprimingwithinactivatedwholesarscov2vaccinecoronavacandboostingwiththeadenoviralvectorchadox1ncov19vaccine |